MINDBIO THERAPEUTICS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.05 CAD | -16.67% |
|
-9.09% | +100.00% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | - | Capitalization | 4.89M 6.65M |
|---|---|---|---|---|---|
| Net income 2022 | -7M -9.53M | Net income 2023 | -4M -5.44M | EV / Sales 2022 * | - |
| Net Debt 2022 | 3.15M 4.28M | Net Debt 2023 | 4.64M 6.31M | EV / Sales 2023 | - |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-2.04
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 88.89% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -16.67% | ||
| 1 week | -9.09% | ||
| Current month | -23.08% | ||
| 3 months | -28.57% | ||
| 6 months | +100.00% | ||
| Current year | +100.00% |
1 week
0.05
0.07
1 month
0.050.07
Current year
0.020.09
1 year
0.020.14
3 years
0.020.79
5 years
0.020.79
10 years
0.020.79
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 0.05 | -16.67% | 154,533 |
| 24-05-16 | 0.06 | -14.29% | 15,144 |
| 24-05-15 | 0.07 | +16.67% | 46,348 |
| 24-05-14 | 0.06 | +9.09% | 34,500 |
| 24-05-13 | 0.055 | 0.00% | 1,000 |
Delayed Quote Canadian Securities Exchange, May 17, 2024 at 03:14 pm EDT
More quotes
MindBio Therapeutics Corp. is a biotechnology company. The Company is focused on creating novel and emerging treatments for mental health conditions and is conducting lysergic acid diethylamide (LSD)-microdosing human clinical trials. It has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development. It has completed Phase I clinical trials microdosing LSD in 80 patients, has a Phase II clinical trial in development microdosing LSD in patients with major depressive disorder, and has a Phase II clinical trial in development microdosing LSD in late-stage cancer patients experiencing existential distress. The Company invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions, to treat debilitating health conditions such as depression, anxiety, and other related mental health conditions.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +100.00% | 4.89M | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- MBIO Stock
